We determined IG-MYC-breakpoints in samples from children with BL/B-AL, risk groups R3 and R4, treated with identical chemotherapy in NHL-BFM studies/-registry between 2000 and 02/2017 (supplementary patient data) for whom frozen or FFPE initial tumor material, and frozen bone marrow cells from either initial punctures (93 BL, for MDD) or before the second course of chemotherapy (50 B-AL, for MRD) were available. Here, MYC is linked to Burkitt lymphoma.